November 20, 2026

A weekly shot of semaglutide, the drug sold as Wegovy, cut body mass index by double digits in children as young as 6 in a new two-year trial. The results put GLP-1 for kids under 12 squarely on the table for the first time, and they come with real questions about side effects, growth and what happens after the shots stop.

The study, called STEP Young, was presented at ObesityWeek 2026 and published simultaneously in the New England Journal of Medicine on Nov. 16. Pediatricians are calling the results striking. They are also urging families not to treat a weight-loss shot as a shortcut for a 7-year-old.

Here is what the research actually found, what the American Academy of Pediatrics (AAP) currently recommends, and the questions worth bringing to your child’s next checkup.

What the New GLP-1 for Kids Study Found

STEP Young was a phase 3, double-blind, placebo-controlled trial run at 48 sites in nine countries. Researchers randomly assigned 167 children ages 6 to 11 with obesity to weekly semaglutide injections or a placebo, in a 2:1 ratio (112 kids on the drug, 55 on placebo). Both groups also got lifestyle counseling.

These were not kids who were a few pounds over a chart line. According to Contemporary Pediatrics, more than 85% had class II or class III obesity, the more severe categories. The average age was 10, and 59% were girls, Healio reported.

The headline numbers

  • BMI at 68 weeks: Down 13.5% on semaglutide versus up 2.7% on placebo, a 16.2 percentage-point difference.
  • BMI at 104 weeks (two years): Down 9.4% on semaglutide versus up 8.4% on placebo.
  • Dropping a BMI category: 79% of kids on the drug versus 23% on placebo.
  • No longer meeting the obesity cutoff (below the 95th percentile for age and sex): 38% versus 2%.
  • At least a 10% BMI drop: 78.7% on semaglutide versus none on placebo, per Healio. Contemporary Pediatrics notes this figure comes from a supportive analysis that was not adjusted for multiple comparisons, so it should be read cautiously.

Doses topped out at 1.7 mg or 2.4 mg a week depending on the child’s starting weight, or whatever dose the child could tolerate.

Beyond the scale

Researchers also tracked heart and blood sugar markers. At 68 weeks, kids on semaglutide saw waist size shrink by 8.5 cm (placebo kids gained 2.7 cm), triglycerides fall 26.3% and systolic blood pressure drop 4.4 points, Healio reported. In an exploratory look at children who started with prediabetes, 93% on the drug had normal blood sugar readings by week 68, compared with 56% on placebo.

“Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life,” lead author Dr. Ania Jastreboff of Yale School of Medicine said, as quoted by Contemporary Pediatrics.

One important note: this is a randomized controlled trial, the strongest type of study for showing that a drug causes an effect. It was also funded by Novo Nordisk, which makes Wegovy, and several investigators disclosed financial ties to drugmakers.

Side Effects, Growth and the “What Happens Next” Problem

Nearly every child in the study had some kind of side effect, but so did nearly every child on placebo: 96% versus 93%. The difference showed up in the stomach.

Side effect Semaglutide Placebo
Vomiting 70% 29%
Diarrhea 62% 35%
Nausea 58% 24%
Serious adverse events 9% 9%
Stopped due to side effects 4% 2%

Source: Healio’s ObesityWeek coverage. Most stomach issues were mild to moderate and clustered during the period when doses were being increased.

That vomiting number is the one pediatricians keep coming back to. “When we talk about 70% of the kids in the semaglutide group,” Dr. Jade Cobern, who is board certified in pediatrics and preventive medicine, told ABC News, the question becomes what that means for a 6-year-old’s school day and daily life.

What about growth?

Growth is a top worry for parents of young kids, and the early data are mixed in how they are being described. ABC News reported that children on semaglutide grew about 1.3 inches less than those on placebo. Investigators presenting the data noted that children with obesity tend to be taller than their peers, and that treatment may slow that accelerated growth, Healio reported.

“We did not see any effects on puberty progression, puberty development or bone mineral density,” study investigator Dr. Antje Körner said at the meeting. Still, a two-year trial cannot tell families what happens to adult height or bones a decade later.

The weight can come back

After two years, the children stopped the drug for a seven-week washout period. BMI started rising again in the semaglutide group during that time, Jastreboff said, while the placebo group kept climbing on the path it was already on. Data from 26 weeks off the drug are expected in the coming months.

That matters because it suggests GLP-1 medication may be a long-term commitment rather than a short course. For a 6-year-old, “long-term” could mean many years.

What the AAP Guideline Says About Obesity Treatment

In January 2023, the AAP issued its first comprehensive clinical practice guideline on evaluating and treating children with obesity. Its core messages still frame how pediatricians approach this new data:

  • No more “wait and see.” “There is no evidence that ‘watchful waiting’ or delayed treatment is appropriate for children with obesity,” guideline author Dr. Sandra Hassink said.
  • Family-based lifestyle treatment comes first. The most effective programs include “26 or more hours of face-to-face, family-based, multicomponent treatment” over 3 to 12 months.
  • Medication starting at 12. Pediatricians “should offer adolescents ages 12 years and older with obesity weight loss pharmacotherapy” as an add-on to lifestyle treatment, not a replacement.
  • Surgery evaluation at 13 and up for teens with severe obesity.

The AAP’s parent-facing summary on HealthyChildren.org stresses that families should be involved “in decision-making at every step of the way.” Healio’s report notes the guideline leaves room for considering medication in children as young as 8, alongside lifestyle care. It also cited a World Health Organization guideline, described by Emory University’s Dr. Daniel Hsia, that reserves medication for 10- and 11-year-olds who don’t respond to lifestyle changes and does not recommend it for kids 9 and younger.

The AAP guideline has had critics too. An editorial in American Family Physician pointed out that long-term evidence on pediatric weight-loss drugs was thin and raised concerns that more intensive weight management could increase weight stigma and disordered eating.

If you are trying to make sense of how obesity itself is being defined, our explainer on the push to look beyond BMI and define “clinical obesity” is a useful companion read.

Is GLP-1 for Kids Available Yet? Approval and Cost

Not for this age group. Wegovy is FDA-approved for adolescents 12 and older, a label it has held since December 2022. As of the ObesityWeek presentations, no GLP-1 drug was approved in the U.S. for children under 12, according to study investigator Dr. Martin Wabitsch, as reported by Healio. ABC News reported that Novo Nordisk plans to seek approval for a younger age group. No FDA timeline has been announced.

That means any use in a 6- to 11-year-old today would be off-label, a decision a doctor would make case by case.

The price tag

Cost is a real barrier. Novo Nordisk’s NovoCare pricing page lists the Wegovy pen at $349 a month for self-pay patients at the standard doses, with a list price of $1,349.02 per package. People with commercial insurance that covers the drug may pay as little as $25 a month through a savings offer, but government beneficiaries are excluded and “eligibility and restrictions apply.”

Coverage for anti-obesity medication varies widely by plan, and an off-label prescription for a young child may face extra hurdles. If your pediatrician brings it up, ask your insurer directly about prior authorization rules.

Parent Q&A: Your GLP-1 for Kids Questions, Answered

Should I ask for this shot for my 8-year-old?

It is reasonable to ask questions, but the drug is not approved for children under 12, and the AAP’s guidance still starts with intensive, family-based lifestyle treatment. Experts interviewed by ABC News stressed that medication is “not the only tool and not the only focus,” in Cobern’s words.

Does this mean diet and exercise don’t work?

No. Every child in STEP Young, including those on placebo, received lifestyle counseling. Some obesity doctors say they “hit a wall in some of these younger age groups” with lifestyle care alone, Cobern noted, which is why researchers wanted to test medication. Everyday habits still matter. Research we covered on ultra-processed foods and kids’ brain responses shows why what’s on the plate is part of the picture.

Which kids were in this study?

Children ages 6 to 11 whose BMI was at or above the 95th percentile, most with more severe obesity. The results may not apply to children with milder obesity or overweight.

Is the drug safe for a young child?

Over two years, researchers reported no new safety signals and the same rate of serious side effects in both groups. But stomach side effects were very common, and effects beyond two years on growth, bones and eating habits are simply unknown.

Why are some doctors excited?

Because severe obesity in childhood often brings high blood pressure, fatty liver and prediabetes. Dr. Mary Pat Gallagher, director of pediatric endocrinology at NYU Langone’s Hassenfeld Children’s Hospital, called the findings “a remarkable result” and said, “I think we have a real problem with childhood obesity.” She described the potential of one treatment “instead of taking a blood pressure medication and some drug to treat fat in your liver,” ABC News reported.

What questions remain?

Hsia, who was not part of the trial, said the results support “a paradigm shift moving away from watchful waiting to earlier treatment of obesity.” He also flagged open questions: which children benefit most, whether different drugs perform differently and what outcomes look like beyond two years.

The Bottom Line: What Parents Should Do Next

STEP Young is the strongest evidence yet that GLP-1 medication can meaningfully lower BMI and improve heart and blood sugar markers in children as young as 6 with severe obesity. It is also a reminder that these drugs bring frequent stomach side effects, uncertain long-term effects and a likely need to stay on them.

  • Talk to your pediatrician. If you are worried about your child’s weight or health, ask for a full evaluation, including blood pressure, blood sugar and liver checks where appropriate. Only your child’s doctor can weigh whether any treatment fits your child.
  • Ask about intensive lifestyle programs. The AAP’s top-line recommendation is family-based care. Ask what is available locally or through your health system.
  • Keep the language kind. Focus on health and energy, not numbers on a scale, to reduce stigma and disordered eating risk.
  • Build small family habits. Shared meals, active time and sleep routines help everyone. Our guide on managing kids’ screen time over Thanksgiving break has practical ideas for the holiday stretch.
  • Watch for updates. More off-drug data are expected in the coming months, and any FDA decision on younger kids is still ahead.

This article is for general information and is not medical advice. Talk to your child’s pediatrician before starting, stopping or changing any treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Copy link
Powered by Social Snap